Rigontec Buy Adds RNA Tech To Merck & Co IO Portfolio

 
• By Lubna Ahmed

Merck & Co. adds to its immuno-oncology pipeline with the acquisition of Rigontec for an upfront payment of €115m, with the three-year-old company offering Merck a unique approach to immunotherapy and a lead candidate currently in Phase I/II trials, the first of its kind in human studies.

Two groups of candies in different colors symbolizing the parties to the negotiations

More from Immuno-oncology

More from Anticancer